Tevogen Bio Holdings announced that it has signed a non‑exclusive, non‑binding Letter of Intent (LOI) to evaluate a potential acquisition of Sciometrix Inc., a Michigan‑based digital care management company. The LOI, signed on February 26 2026, would give Tevogen a majority voting interest in Sciometrix if the transaction closes.
The deal would combine Sciometrix’s Clinicus platform, which delivers remote patient monitoring and value‑based care solutions, with Tevogen’s AI‑driven drug discovery platform, Tevogen.AI. The integration is intended to create a comprehensive ecosystem that supports patients across socioeconomic backgrounds and could generate new revenue streams for Tevogen, which has been pre‑revenue and has reported operating losses of $10.37 million in Q1 2025 and $21.6 million for the nine months ended September 30 2025.
Tevogen’s core business remains the development of off‑the‑shelf precision T‑cell therapies through its ExacTcell platform for cancers and viral infections. The company’s strategic shift toward revenue‑generating services is driven by liquidity constraints and a Nasdaq minimum bid price deficiency that requires compliance by March 23 2026. The acquisition of Sciometrix could diversify Tevogen’s revenue base and provide a cash‑flow cushion while accelerating commercialization of its virology and oncology programs.
"Our objective is to build a fully integrated healthcare ecosystem designed to support patients across all socioeconomic backgrounds. This proposed transaction, if completed, could further advance that vision," said Dr. Ryan Saadi, founder and CEO of Tevogen. "Today marks a major milestone for Sciometrix and Clinicus and the many patients who rely on our high‑quality, cost‑effective digital healthcare platform to deliver healthcare in their own environment. Our comprehensive care management service has achieved major milestones in the past year, resulting in Sciometrix becoming a top 25 digital healthcare company in the USA," added Abhishek Sharma, founder and CEO of Sciometrix.
The LOI is non‑binding and subject to due diligence, negotiation of definitive terms, and regulatory approvals. If the transaction closes, Tevogen would hold a majority voting interest in Sciometrix and would be positioned to leverage its precision T‑cell platform within a larger digital health framework, potentially accelerating the commercialization of its pipeline and addressing its liquidity challenges.
The announcement signals a major strategic pivot for Tevogen, moving from a purely clinical‑stage biopharma focus to a broader healthcare services model that could reshape its revenue trajectory and risk profile.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.